Valneva SE (ADR)
General ticker "VALN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $537.7M (TTM average)
Valneva SE (ADR) follows the US Stock Market performance with the rate: 46.4%.
Estimated limits based on current volatility of 2.2%: low 8.63$, high 9.02$
Factors to consider:
- Total employees count: 762 as of 2021
- Current price 24.8% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.64$, 7.08$]
- 2025-12-31 to 2026-12-31 estimated range: [2.70$, 7.01$]
Financial Metrics affecting the VALN estimates:
- Positive: with PPE of -24.5 at the end of fiscal year the price was very low
- Positive: 7.86 < Operating profit margin, % of 7.86
- Negative: Operating cash flow per share per price, % of -23.91 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 36.25 <= 41.86
- Positive: Investing cash flow per share per price, % of 27.36 > -0.66
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -2.39
Short-term VALN quotes
Long-term VALN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €361.30MM | €153.71MM | €169.58MM |
| Operating Expenses | €474.75MM | €235.80MM | €156.25MM |
| Operating Income | €-113.44MM | €-82.09MM | €13.33MM |
| Non-Operating Income | €-31.37MM | €-16.54MM | €-24.82MM |
| Interest Expense | €19.05MM | €23.32MM | €23.98MM |
| R&D Expense | €104.92MM | €59.89MM | €74.14MM |
| Income(Loss) | €-144.81MM | €-98.63MM | €-11.49MM |
| Taxes | €-1.54MM | €2.80MM | €0.76MM |
| Profit(Loss)* | €-143.28MM | €-101.43MM | €-12.25MM |
| Stockholders Equity | €219.80MM | €128.25MM | €181.25MM |
| Inventory | €35.10MM | €44.47MM | €53.66MM |
| Assets | €621.34MM | €460.06MM | €500.03MM |
| Operating Cash Flow | €-245.34MM | €-202.74MM | €-67.22MM |
| Capital expenditure | €29.32MM | €14.31MM | €16.44MM |
| Investing Cash Flow | €-29.05MM | €-20.59MM | €76.92MM |
| Financing Cash Flow | €215.12MM | €63.08MM | €30.68MM |
| Earnings Per Share** | €-2.48 | €-1.46 | €-0.17 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.